CNS Pharmaceuticals, Inc. announced it has appointed Amy Mahery to its Board of Directors, effective upon completion of a financing. Ms. Mahery, who currently serves as the Chief Commercial Officer of Roivant Sciences, is a well-established biopharmaceutical industry veteran with more than 20 years of experience and commercial expertise working with large and small companies in common and rare conditions, and across multiple therapeutic areas. Over the course of her distinguished career, she has held diverse global and U.S. commercial leadership roles spanning sales, marketing, and market access where she has been involved in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and immunology.

During her tenures at market-leading companies she has been responsible for developing high-impact commercial strategies that delivered profitable growth across multibillion-dollar product portfolios on a global scale. Additionally, in her work at emerging biopharma companies, she has built commercial capabilities from the startup phase to enable the commercialization of first-in-class and best-in-class assets. As the Chief Commercial Officer (CCO) of Roivant Sciences, Ms. Mahery is playing a key role in facilitating the company's transformation from a clinical development-focused organization to an end-to-end biotech leader.

While working to establish Roivant's commercial operation and capability, enabling profitable growth across the entire portfolio of 10+ affiliate Vant companies, she also provides direct commercial leadership to Vants during the start-up phase. Most notably, she served as CCO of Telavant from inception through its sale to Roche for $7.1 Billion. Prior to Roivant, Ms. Mahery held multiple leadership roles at EMD Serono, Inc. (Merck KGaA).

Most recently, she served as Senior Vice President and Head of Global Franchise, Neurology and Immunology (N&I) at EMD Serono where she developed and led the implementation of the end-to-end franchise strategy and managed the global P&L for the N&I portfolio. Prior to that, she led worldwide access strategy development across Oncology, Neurology, Immunology, Fertility, and General Medicines to create advanced approaches to pricing, reimbursement, and patient access as Senior Vice President and Head of Global Market Access and Pricing. Ms. Mahery holds a holds a B.S. in Neuroscience from Trinity College.